LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Search

Ionis Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

73.25 2.56

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

70.45

Max

74.35

Galvenie mērījumi

By Trading Economics

Ienākumi

-252M

-129M

Pārdošana

-295M

157M

EPS

-0.613

Peļņas marža

-82.062

Darbinieki

1,069

EBITDA

-263M

-112M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+18.56% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-370M

11B

Iepriekšējā atvēršanas cena

70.69

Iepriekšējā slēgšanas cena

73.25

Ziņu noskaņojums

By Acuity

50%

50%

185 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

Ionis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 17. nov. 18:59 UTC

Galvenie tirgus virzītāji

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

2025. g. 17. nov. 23:40 UTC

Tirgus saruna

Gold Consolidates Amid Mixed Signals -- Market Talk

2025. g. 17. nov. 23:34 UTC

Tirgus saruna

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2025. g. 17. nov. 22:58 UTC

Tirgus saruna

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

2025. g. 17. nov. 22:46 UTC

Tirgus saruna

Risk Assets Set to Have a Strong 2026 -- Market Talk

2025. g. 17. nov. 22:06 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

2025. g. 17. nov. 22:02 UTC

Peļņas

Trip.com Group 3Q Rev $2.6B >TCOM

2025. g. 17. nov. 22:02 UTC

Peļņas

Trip.com Group 3Q Adj EPS $3.87 >TCOM

2025. g. 17. nov. 22:02 UTC

Peļņas

Trip.com Group 3Q EPS $4.02 >TCOM

2025. g. 17. nov. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 17. nov. 21:40 UTC

Peļņas

James Hardie Industries 2Q Adj EPS 26c >JHX

2025. g. 17. nov. 21:40 UTC

Peļņas

James Hardie Industries 2Q Loss/Shr 10c >JHX

2025. g. 17. nov. 21:39 UTC

Peļņas

James Hardie Industries 2Q Sales $1.29B >JHX

2025. g. 17. nov. 21:38 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

2025. g. 17. nov. 21:38 UTC

Peļņas

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

2025. g. 17. nov. 21:10 UTC

Peļņas

XP Inc. 3Q EPS BRL2.47 >XP

2025. g. 17. nov. 21:10 UTC

Peļņas

XP Inc. 3Q Rev BRL4.67B >XP

2025. g. 17. nov. 20:20 UTC

Tirgus saruna

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

2025. g. 17. nov. 20:12 UTC

Tirgus saruna

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

2025. g. 17. nov. 20:12 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. nov. 20:09 UTC

Tirgus saruna

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

2025. g. 17. nov. 19:29 UTC

Tirgus saruna

Gold Slide Continues to Start Week -- Market Talk

2025. g. 17. nov. 19:16 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

2025. g. 17. nov. 18:20 UTC

Iegādes, apvienošanās, pārņemšana

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

2025. g. 17. nov. 16:45 UTC

Iegādes, apvienošanās, pārņemšana

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

2025. g. 17. nov. 16:16 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

2025. g. 17. nov. 16:15 UTC

Peļņas

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

2025. g. 17. nov. 15:40 UTC

Iegādes, apvienošanās, pārņemšana

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

2025. g. 17. nov. 15:22 UTC

Iegādes, apvienošanās, pārņemšana

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

2025. g. 17. nov. 15:19 UTC

Tirgus saruna

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Salīdzinājums

Cenas izmaiņa

Ionis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

18.56% augšup

Prognoze 12 mēnešiem

Vidējais 84.83 USD  18.56%

Augstākais 110 USD

Zemākais 65 USD

Pamatojoties uz 20 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

20 ratings

17

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

29.78 / 33.645Atbalsts un pretestība

Īstermiņā

Neutral Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

185 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat